BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Locatelli F, Covic A, Eckardt K, Wiecek A, Vanholder R; on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2008;24:348-54. [DOI: 10.1093/ndt/gfn653] [Cited by in Crossref: 129] [Cited by in F6Publishing: 94] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Numan S, Kaluza K. Systematic review of guidelines for the diagnosis and treatment of iron deficiency anemia using intravenous iron across multiple indications. Curr Med Res Opin 2020;36:1769-82. [PMID: 32936683 DOI: 10.1080/03007995.2020.1824898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Szeto CC, Lo WK, Li PK. Clinical practice guidelines for the provision of renal service in Hong Kong: Peritoneal Dialysis. Nephrology 2019;24:27-40. [DOI: 10.1111/nep.13505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Morosetti M, Gorini A, Costanzo AM, Cipriani S, Dominijanni S, Egan CG, Zappalà L, di Luzio Paparatti U. Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients). Int J Nephrol Renovasc Dis 2013;6:27-37. [PMID: 23550080 DOI: 10.2147/IJNRD.S38405] [Reference Citation Analysis]
4 Alves MT, Vilaça SS, Carvalho Md, Fernandes AP, Dusse LM, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter 2015;37:190-7. [PMID: 26041422 DOI: 10.1016/j.bjhh.2015.02.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
5 Uhlinova J, Pechter U, Kermes K, Ots-Rosenberg M. Peritoneal Dialysis Penetration and Peritonitis Rate at a Single Centre during Last Decade. Int J Nephrol 2011;2011:470426. [PMID: 21747997 DOI: 10.4061/2011/470426] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrol 2021;22:284. [PMID: 34419007 DOI: 10.1186/s12882-021-02491-y] [Reference Citation Analysis]
7 Rostoker G, Griuncelli M, Loridon C, Magna T, Machado G, Drahi G, Dahan H, Janklewicz P, Cohen Y. Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. PLoS One 2015;10:e0132006. [PMID: 26182077 DOI: 10.1371/journal.pone.0132006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
8 Saunders MR, Lee H, Chin MH. Early winners and losers in dialysis center pay-for-performance. BMC Health Serv Res 2017;17:816. [PMID: 29216894 DOI: 10.1186/s12913-017-2764-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
9 O'Lone EL, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2019;2:CD007857. [PMID: 30790278 DOI: 10.1002/14651858.CD007857.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
10 Rostoker G, Vaziri ND. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. Heliyon 2019;5:e02045. [PMID: 31338466 DOI: 10.1016/j.heliyon.2019.e02045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
11 Rostoker G, Vaziri ND. Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution. Hemodial Int 2017;21 Suppl 1:S68-77. [PMID: 28332306 DOI: 10.1111/hdi.12557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
12 Rostoker G, Vaziri ND, Fishbane S. Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century. Drugs. 2016;76:741-757. [PMID: 27091216 DOI: 10.1007/s40265-016-0569-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
13 Moradi Z, Maali A, Shad JS, Farasat A, Kouchaki R, Moghadami M, Ahmadi MH, Azad M. Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach. Indian J Hematol Blood Transfus 2020;36:26-36. [PMID: 32174689 DOI: 10.1007/s12288-019-01170-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Vanholder R, Davenport A, Hannedouche T, Kooman J, Kribben A, Lameire N, Lonnemann G, Magner P, Mendelssohn D, Saggi SJ, Shaffer RN, Moe SM, Van Biesen W, van der Sande F, Mehrotra R; on behalf of the Dialysis Advisory Group of the American Society of Nephrology. Reimbursement of Dialysis: A Comparison of Seven Countries. JASN 2012;23:1291-8. [DOI: 10.1681/asn.2011111094] [Cited by in Crossref: 89] [Cited by in F6Publishing: 34] [Article Influence: 8.9] [Reference Citation Analysis]
15 Cullis JO. Diagnosis and management of anaemia of chronic disease: current status: Review. British Journal of Haematology 2011;154:289-300. [DOI: 10.1111/j.1365-2141.2011.08741.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
16 Galle JC, Addison J, Suranyi MG, Claes K, Di Giulio S, Guerin A, Herlitz H, Kiss I, Farouk M, Manamley N, Wirnsberger G, Winearls C. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. Nephrol Dial Transplant 2016;31:2073-85. [PMID: 27190334 DOI: 10.1093/ndt/gfw047] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Fernandez H, Singh AK. Management of Anemia in Chronic Kidney Disease. Chronic Renal Disease. Elsevier; 2015. pp. 624-33. [DOI: 10.1016/b978-0-12-411602-3.00051-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Gesualdo L, Combe C, Covic A, Dellanna F, Goldsmith D, London G, Mann JF, Zaoui P, Turner M, Muenzberg M, MacDonald K, Abraham I. Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). Int Urol Nephrol 2015;47:837-45. [PMID: 25894959 DOI: 10.1007/s11255-015-0970-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Issad B, Ghali N, Beaudreuil S, Griuncelli M, Cohen Y, Rostoker G. Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis. Kidney Int Rep 2017;2:1219-22. [PMID: 29270530 DOI: 10.1016/j.ekir.2017.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
20 Sá Martins V, Adragão T, Aguiar L, Pinto I, Dias C, Figueiredo R, Lourenço P, Pascoal T, Pereira J, Pinheiro T, Ramião I, Velez B, Papoila AL, Borges N, Calhau C, Macário F. Prognostic Value of the Malnutrition-inflammation Score in Hospitalization and Mortality on Long-term Hemodialysis. J Ren Nutr 2021:S1051-2276(21)00271-5. [PMID: 34922814 DOI: 10.1053/j.jrn.2021.11.002] [Reference Citation Analysis]
21 Gesualdo L, London G, Turner M, Lee C, Macdonald K, Goldsmith D, Covic A, Zaoui P, Combe C, Mann J, Dellanna F, Muenzberg M, Abraham I. A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Intern Emerg Med 2013;8:389-99. [DOI: 10.1007/s11739-011-0622-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Evans M, Suttorp MM, Bellocco R, Hoekstra T, Qureshi AR, Dekker FW, Carrero JJ. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant 2016;31:628-35. [PMID: 26243782 DOI: 10.1093/ndt/gfv298] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
23 Rodriguez-iturbe B, Correa-rotter R. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opinion on Pharmacotherapy 2010;11:2687-98. [DOI: 10.1517/14656561003796570] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
24 Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 2017;1:CD011690. [PMID: 28066881 DOI: 10.1002/14651858.CD011690.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Coronado Daza JA, Cuchi GU. Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients. Indian J Nephrol 2019;29:160-5. [PMID: 31142961 DOI: 10.4103/ijn.IJN_124_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Liabeuf S, Van Stralen KJ, Caskey F, Tentori F, Pisoni RL, Sajjad A, Jager KJ, Massy ZA. Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce? Nephrol Dial Transplant 2017;32:1737-49. [PMID: 28057873 DOI: 10.1093/ndt/gfw409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
27 Holt S, Goldsmith D. Renal Association Clinical Practice Guideline on cardiovascular disease in CKD. Nephron Clin Pract 2011;118 Suppl 1:c125-44. [PMID: 21555891 DOI: 10.1159/000328065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
28 Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, Conte G, De Nicola L, Mangione F, Esposito P, Dal Canton A; REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013;28:3035-45. [PMID: 24145459 DOI: 10.1093/ndt/gft338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
29 Portolés-Pérez J, Durá-Gúrpide B, Merino-Rivas JL, Martín-Rodriguez L, Hevia-Ojanguren C, Burguera-Vion V, Yuste-Lozano C, Sánchez-García L, Rodriguez-Palomares JR, Paraiso V; GCDP Study Group. Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study. Clin Kidney J 2021;14:174-80. [PMID: 33564416 DOI: 10.1093/ckj/sfz153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Rostoker G, Griuncelli M, Loridon C, Magna T, Janklewicz P, Drahi G, Dahan H, Cohen Y. Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis. PLoS One 2014;9:e115096. [PMID: 25506921 DOI: 10.1371/journal.pone.0115096] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
31 Kõlvald K, Pechter U, Luman M, Ilmoja M, Ots-Rosenberg M. Improvements in renal replacement therapy practice patterns in estonia. Nephron Extra 2014;4:108-18. [PMID: 25177339 DOI: 10.1159/000363349] [Reference Citation Analysis]
32 Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25:2846-2850. [PMID: 20591813 DOI: 10.1093/ndt/gfq336] [Cited by in Crossref: 95] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
33 Gabutti L, Nobile F, Forni V, Rigamonti F, Weibel N, Burnier M. Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: is it feasible? BMC Nephrol 2011;12:11. [PMID: 21332992 DOI: 10.1186/1471-2369-12-11] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Malyszko J, Oberbauer R, Watschinger B. Anemia and erythrocytosis in patients after kidney transplantation. Transpl Int. 2012;25:1013-1023. [PMID: 22716097 DOI: 10.1111/j.1432-2277.2012.01513.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
35 Ito H, Takeuchi Y, Ishida H, Otawa A, Shibayama A, Antoku S, Abe M, Mifune M, Togane M. Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig 2010;1:273-8. [PMID: 24843443 DOI: 10.1111/j.2040-1124.2010.00060.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
36 Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28:1346-59. [PMID: 23585588 DOI: 10.1093/ndt/gft033] [Cited by in Crossref: 210] [Cited by in F6Publishing: 176] [Article Influence: 23.3] [Reference Citation Analysis]
37 Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. [PMID: 33842503 DOI: 10.3389/fmed.2021.642296] [Reference Citation Analysis]
38 Locatelli F, Andrulli S, Viganò SM, Concetti M, Urbini S, Giacchino F, Broccoli R, Aucella F, Cossu M, Conti P, Fattori L, Punzo G, Angelini D, Peruzzini M, Di Giulio S, Piroddi M, Galli F, Del Vecchio L. Evaluation of the Impact of a New Synthetic Vitamin E-Bonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study. Blood Purif 2017;43:338-45. [PMID: 28249254 DOI: 10.1159/000453442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
39 Gupta G, Chatterjee A, Kumar M, Sardar P, Varghese T, Srivastava PP, Gupta S. Efficacy of single and multiple doses of fenbendazole against gill parasites ( Dactylogyrus sp.) of Labeo rohita (Hamilton, 1822) and its physio‐metabolic effects on the fish. Aquac Res 2019;51:1190-9. [DOI: 10.1111/are.14470] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant 2014;2014:179705. [PMID: 24883202 DOI: 10.1155/2014/179705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Akizawa T, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Yamamoto H. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. BMJ Open 2019;9:e026602. [PMID: 31203241 DOI: 10.1136/bmjopen-2018-026602] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
42 Ahsan MN, Asif N, Khanzada SW, Asghar MS, Yasmin F, Khalid F, Fareed S, Irshad SG. Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study. J Community Hosp Intern Med Perspect 2021;11:782-6. [PMID: 34804391 DOI: 10.1080/20009666.2021.1983980] [Reference Citation Analysis]
43 Alcalde-bezhold G, Alcázar-arroyo R, Angoso-de-guzmán M, Arenas MD, Arias-guillén M, Arribas-cobo P, Díaz-gómez JM, García-maset R, González-parra E, Hernández-marrero D, Herrero-calvo JA, Maduell F, Molina P, Molina-núñez M, Otero-gonzález A, Pascual J, Pereira-garcía M, Pérez-garcía R, Dolores del Pino y Pino M, Prieto-velasco M, Pulido JFP, Sánchez-álvarez JE, Sánchez-hernández R, de Sequera-ortiz P. Hemodialysis Centers Guide 2020. Nefrología (English Edition) 2021;41:1-77. [DOI: 10.1016/s2013-2514(22)00042-6] [Reference Citation Analysis]
44 Ito H, Antoku S, Furusho M, Shinozaki M, Abe M, Mifune M, Togane M, Ito K, Sanaka T. The Prevalence of the Risk Factors for Atherosclerosis among Type 2 Diabetic Patients Is Greater in the Progressive Stages of Chronic Kidney Disease. Nephron Extra 2013;3:66-72. [PMID: 23904855 DOI: 10.1159/000353592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
45 Capone D, Cataldi M, Vinciguerra M, Mosca T, Barretta S, Ragosta A, Sorrentino A, Vecchione A, Barretta L, Tarantino G. Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study. In Vivo 2017;31:709-12. [PMID: 28652444 DOI: 10.21873/invivo.11118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
46 Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, Foote B, Hedman K, James G, Lopes AA, Massy Z, Reichel H, Sloand J, Waechter S, Wong MMY, Pecoits-Filho R. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep 2021;11:1784. [PMID: 33469061 DOI: 10.1038/s41598-020-79254-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 . Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:292-8. [PMID: 25018949 DOI: 10.1038/kisup.2012.34] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
48 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
49 Heidenreich S, Leistikow F, Zinn S, Baumann J, Atzeni A, Bajeski V, Dietzmann J, Dragoun GP; SUPRA Study Group. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investig 2012;32:99-110. [PMID: 22117178 DOI: 10.2165/11594040-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 de Francisco AL. Individualizing anaemia therapy. NDT Plus 2010;3:519-26. [PMID: 25949459 DOI: 10.1093/ndtplus/sfq164] [Reference Citation Analysis]
51 Rostoker G, Vaziri ND. Iatrogenic iron overload and its potential consequences in patients on hemodialysis. Presse Med 2017;46:e312-28. [PMID: 29153377 DOI: 10.1016/j.lpm.2017.10.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
52 Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-80. [PMID: 20706990 DOI: 10.1002/ajh.21805] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
53 Sobrado CW, Cançado RD, Sobrado LF, Frugis MO, Sobrado MF. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose. Arq Gastroenterol 2015;52:255-9. [DOI: 10.1590/s0004-28032015000400002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
54 Urrechaga E, Hoffmann JJML. Assessment of iron-restricted erythropoiesis in chronic renal disease: evaluation of Abbott CELL-DYN Sapphire mean reticulocyte hemoglobin content (MCHr). Scandinavian Journal of Clinical and Laboratory Investigation 2019;79:363-7. [DOI: 10.1080/00365513.2019.1622149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014;29:843-50. [PMID: 24170814 DOI: 10.1093/ndt/gft424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
56 Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, Cozzolino M. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrology Dialysis Transplantation 2012;27:122-7. [DOI: 10.1093/ndt/gfr284] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
57 Kessler M, Landais P, Bataille P, Yver L, Koné S, Kraemer S, Brillet G, Canivet E. [Anemia management in French hemodialysis patients: DiaNE study results at 3 years (DiaNE2)]. Nephrol Ther 2011;7:182-7. [PMID: 21227765 DOI: 10.1016/j.nephro.2010.11.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Fusco G, Hariri A, Vallarino C, Singh A, Yu P, Wise L. A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease. Ther Adv Drug Saf 2017;8:305-18. [PMID: 29593859 DOI: 10.1177/2042098617716819] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011;26:3262-7. [PMID: 21355067 DOI: 10.1093/ndt/gfr024] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
60 Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali C, London GM. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant. 2010;25:3823-3831. [PMID: 20829401 DOI: 10.1093/ndt/gfq513] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
61 Więcek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther 2010;27:941-52. [PMID: 20972656 DOI: 10.1007/s12325-010-0080-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
62 Daugas É, Dussol B, Henri P, Joly D, Juillard L, Michaut P, Mourad G, Stroumza P, Touam M. PREPARE – étude transversale observationnelle sur la prise en charge de l’insuffisance rénale chronique en néphrologie avant le stade d’épuration extrarénale en France. Néphrologie & Thérapeutique 2012;8:439-50. [DOI: 10.1016/j.nephro.2012.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
63 Malyszko J, Basak G, Batko K, Capasso G, Capasso A, Drozd-Sokolowska J, Krzanowska K, Kulicki P, Matuszkiewicz-Rowinska J, Soler MJ, Sprangers B, Malyszko J. Haematological disorders following kidney transplantation. Nephrol Dial Transplant 2020:gfaa219. [PMID: 33150431 DOI: 10.1093/ndt/gfaa219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Palaneeswari M S, Rajan PM, Silambanan S, Jothimalar. Blood Arsenic and Cadmium Concentrations in End-Stage Renal Disease Patients who were on Maintenance Haemodialysis. J Clin Diagn Res 2013;7:809-13. [PMID: 23814716 DOI: 10.7860/JCDR/2013/5351.2945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
65 Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant 2012;27:2303-11. [PMID: 22140136 DOI: 10.1093/ndt/gfr677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
66 Cases A, Portolés J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Int Urol Nephrol 2014;46:1983-95. [PMID: 25118611 DOI: 10.1007/s11255-014-0800-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Karaboyas A, Morgenstern H, Pisoni RL, Zee J, Vanholder R, Jacobson SH, Inaba M, Loram LC, Port FK, Robinson BM. Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2018;33:2234-44. [PMID: 30010940 DOI: 10.1093/ndt/gfy190] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
68 Liabeuf S, Sajjad A, Kramer A, Bieber B, Mccullough K, Pisoni R, Caskey F, Combe C, Robinson BM, Jager KJ, Massy ZA. Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS). Nephrology Dialysis Transplantation 2019;34:2105-10. [DOI: 10.1093/ndt/gfz049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
69 Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, Monk TG. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106:13-22. [PMID: 21148637 DOI: 10.1093/bja/aeq361] [Cited by in Crossref: 320] [Cited by in F6Publishing: 275] [Article Influence: 29.1] [Reference Citation Analysis]
70 Peters NO, Jay N, Cridlig J, Rostoker G, Frimat L. Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. BMC Nephrol 2017;18:97. [PMID: 28320343 DOI: 10.1186/s12882-017-0513-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
71 Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-monros A, Tordoir J, Van Biesen W. Catheter-related blood stream infections (CRBSI): a European view. Nephrology Dialysis Transplantation 2010;25:1753-6. [DOI: 10.1093/ndt/gfq205] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
72 Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study. PLoS One 2017;12:e0179608. [PMID: 28662118 DOI: 10.1371/journal.pone.0179608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
73 Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009; 15(37): 4675-4685 [PMID: 19787831 DOI: 10.3748/wjg.15.4675] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
74 Fliser D, Dellanna F, Koch M, Seufert J, Witzke O, Hauser I. The PRIMAVERA study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemporary Clinical Trials 2011;32:786-92. [DOI: 10.1016/j.cct.2011.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
75 Covic A, Gusbeth-Tatomir P. Trace elements in end-stage renal disease--unfamiliar territory to be revealed. BMC Nephrol 2009;10:12. [PMID: 19490615 DOI: 10.1186/1471-2369-10-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
76 Vigneau C, Choukroun G, Isnard-Bagnis C, Pau D, Sinnasse-Raymond G, Pibre S, Moranne O. "Doctor, can I have less frequent injection with highly efficient treatment?" A patient centered study using an electronic choice-based conjoint analysis (ePRO) to assess real world preferences regarding erythropoiesis stimulating agent to treat anaemia in chronic kidney disease (PERCEPOLIS study). Nephrol Ther 2019;15:152-61. [PMID: 30962139 DOI: 10.1016/j.nephro.2018.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
77 Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordoir J, Van Biesen W. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). NDT Plus. 2010;3:234-246. [PMID: 30792802 DOI: 10.1093/ndtplus/sfq041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
78 Majernikova M, Rosenberger J, Prihodova L, Jarcuskova M, Roland R, Groothoff JW, van Dijk JP. Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients. Biomed Res Int 2017;2017:6987240. [PMID: 28401160 DOI: 10.1155/2017/6987240] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
79 Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012;125:991-999.e1. [PMID: 22998881 DOI: 10.1016/j.amjmed.2012.01.015] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 10.6] [Reference Citation Analysis]
80 Mandolfo S, Corradi B, Bucci R, Farina M, Pilolli F, Galli F. Evaluation of the impact of a new synthetic vitamin E-bonded membrane on anemia and rHuEPO requirement in ESRD patients with central venous catheters: a pilot study. Int Urol Nephrol. 2012;44:1493-1500. [PMID: 21960369 DOI: 10.1007/s11255-011-0016-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
81 Locatelli F, Gascón P. Is Nephrology More at Ease Than Oncology with Erythropoiesis‐Stimulating Agents? Treatment Guidelines and an Update on Benefits and Risks. The Oncol 2009;14:57-62. [DOI: 10.1634/theoncologist.2009-s1-57] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Rostoker G. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? Semin Dial 2019;32:22-9. [PMID: 29956370 DOI: 10.1111/sdi.12732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
83 Tsubakihara Y. To treat or not to treat renal anemia of chronic kidney disease patients? Ther Apher Dial 2010;14:235-9. [PMID: 20609177 DOI: 10.1111/j.1744-9987.2010.00835.x] [Reference Citation Analysis]
84 Weinreich T, Leistikow F, Hartmann HG, Vollgraf G, Dellanna F; SESAM Study Group. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int 2012;16:11-9. [PMID: 22098689 DOI: 10.1111/j.1542-4758.2011.00608.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Locatelli F, Becker H. Update on Anemia Management in Nephrology, Including Current Guidelines on the Use of Erythropoiesis‐Stimulating Agents and Implications of the Introduction of “Biosimilars”. The Oncol 2009;14:16-21. [DOI: 10.1634/theoncologist.2009-s1-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
86 Murkamilov IT, Gordeev IG, Kaliev RR. [The role of renal anemia and cardiovascular disease in the progression of chronic glomerulonephritis]. Ter Arkh 2016;88:57-61. [PMID: 28139561 DOI: 10.17116/terarkh2016881257-61] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, Pisoni R, de Moraes TP, Pecoits-Filho R, Baena CP. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol 2020;21:259. [PMID: 32641153 DOI: 10.1186/s12882-020-01912-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Yarnoff BO, Hoerger TJ, Simpson SA, Pavkov ME, Burrows NR, Shrestha SS, Williams DE, Zhuo X. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. PLoS One 2016;11:e0157323. [PMID: 27404556 DOI: 10.1371/journal.pone.0157323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Frimat L, Mariat C, Landais P, Koné S, Commenges B, Choukroun G. Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open 2013;3:e001888. [PMID: 23474787 DOI: 10.1136/bmjopen-2012-001888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
90 Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 2014;39:130-41. [PMID: 24513913 DOI: 10.1159/000358336] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
91 Urrechaga E, Borque L, Escanero JF. Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis. Biomed Res Int 2013;2013:603786. [PMID: 23555091 DOI: 10.1155/2013/603786] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
92 Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, Glowacki F, Moulin B, Lebranchu Y, Touchard G. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360-368. [PMID: 22193388 DOI: 10.1681/asn.2011060546] [Cited by in Crossref: 68] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
93 Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102:1585-1594. [PMID: 26561626 DOI: 10.3945/ajcn.114.103366] [Cited by in Crossref: 113] [Cited by in F6Publishing: 92] [Article Influence: 16.1] [Reference Citation Analysis]
94 Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open 2019;9:e026704. [PMID: 31203242 DOI: 10.1136/bmjopen-2018-026704] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
95 Hasegawa T, Bragg-gresham JL, Pisoni RL, Robinson BM, Fukuhara S, Akiba T, Saito A, Kurokawa K, Akizawa T. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney International 2011;79:340-6. [DOI: 10.1038/ki.2010.382] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
96 Vanholder R, Abramowicz D, Cannata-Andia JB, Cocchi V, Cochat P, Covic A, Eckardt KU, Fouque D, Heimburger O, Jenkins S, MacLeod A, Lindley E, Locatelli F, London G, Marti I Monros A, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Wiecek A, Zoccali C. The future of European Nephrology 'Guidelines'-a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2009;2:213-21. [PMID: 25983994 DOI: 10.1093/ndtplus/sfp035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
97 Hanafusa N, Nomura T, Hasegawa T, Nangaku M. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant 2014;29:2316-26. [PMID: 25150218 DOI: 10.1093/ndt/gfu272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
98 Bhandari S. Iron therapy in patients with chronic kidney disease: IRON THERAPY IN CHRONIC KIDNEY DISEASE. Transfusion Alternatives in Transfusion Medicine 2012;12:115-21. [DOI: 10.1111/j.1778-428x.2012.01156.x] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013;28:2570-9. [PMID: 24078642 DOI: 10.1093/ndt/gft062] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
100 Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73:117-30. [PMID: 23338536 DOI: 10.1007/s40265-012-0002-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
101 Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2016;27:2205-15. [PMID: 26582402 DOI: 10.1681/ASN.2015060673] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
102 Koch M, Treiber W, Fliser D. Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study. Clin Drug Investig 2013;33:699-706. [PMID: 23975657 DOI: 10.1007/s40261-013-0091-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
103 Rostoker G, Hummel A, Chantrel F, Ryckelynck J. Actualités sur la prise en charge de l’anémie et de la carence martiale du dialysé. Néphrologie & Thérapeutique 2014;10:221-7. [DOI: 10.1016/j.nephro.2014.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
104 Joksimovic Jovic J, Antic S, Nikolic T, Andric K, Petrovic D, Bolevich S, Jakovljevic V, Giustarini D. Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress. Oxidative Medicine and Cellular Longevity 2022;2022:1-10. [DOI: 10.1155/2022/9598211] [Reference Citation Analysis]
105 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
106 Locatelli F, Choukroun G, Truman M, Wiggenhauser A, Fliser D. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials. Adv Ther 2016;33:610-25. [PMID: 26965694 DOI: 10.1007/s12325-016-0309-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
107 Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011;22:358-65. [PMID: 21164028 DOI: 10.1681/ASN.2010020173] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
108 von Haehling S, Ottenjann H, Anker SD. Eisenmangel: Erkennen und behandeln. Internist 2017;58:627-38. [DOI: 10.1007/s00108-017-0242-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
109 Vera-Aviles M, Vantana E, Kardinasari E, Koh NL, Latunde-Dada GO. Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. Pharmaceuticals (Basel) 2018;11:E111. [PMID: 30347874 DOI: 10.3390/ph11040111] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
110 Locatelli F. Iron treatment and the TREAT trial. NDT Plus 2011;4:i3-5. [PMID: 27046442 DOI: 10.1093/ndtplus/sfr041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Gurgel TC, Cherchiglia ML, Acurcio Fde A, Szuster DA, Gomes IC, Andrade EI. [Erythropoietin use by incident hemodialysis patients in the Brazilian Unified National Health System, 2002-2003]. Cad Saude Publica 2012;28:856-68. [PMID: 22641509 DOI: 10.1590/s0102-311x2012000500005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]